Navigation Links
BioVex Raises $40 Million in First Close of Series F Financing
Date:3/30/2009

>About OncoVEX GM-CSF Phase II Clinical Trial

BioVex recently concluded a 50-patient Phase II trial for OncoVEX GM-CSF as a standalone therapy in patients with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure overall objective response, which is defined as a complete response (CR), where disease is completely eliminated, or partial response (PR), where there is a >50% reduction in disease burden. 87% of patients who entered the study were progressing after having failed prior therapy. 13 objective systemic responses (26% objective response rate) were achieved including eight CRs. Eleven responses have so far continued for more than 6 months (range 5-28+ months). Responses were observed in patients with all stages of disease, including the complete resolution of un-injected visceral deposits.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX GM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX GM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEX GM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.

The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides comple
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioVex to Present at the UBS Global Life Sciences Conference
2. BioVex Closes Second Round of Series E Financing
3. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Moodys Raises Boston Scientifics Rating Outlook to Stable
6. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
7. Eiger BioPharmaceuticals Raises $7.1 Million A Round
8. NanoBio Corporation Raises $12 Million in Series B Financing
9. Divergence Raises $11.8 Million in Series C Financing
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... 21, 2011 Cephalon, Inc. (NASDAQ: CEPH ... Consent Revocation Statement with the Securities and Exchange Commission ... proposals to remove Cephalon,s entire Board of Directors and ... mailed copies of the Statement to shareholders of record ...
... Collins Stewart LLC is pleased to announce the ... Beal Advisors and Liberty Tree Advisors. The purpose of ... and private equity transactions in the healthcare sector. Both ... healthcare advisory firms. Georgia Erbez – founder of Beal ...
... Calif., April 21, 2011 The Stanford University ... the initiation of a Phase 1/2a clinical trial ... allogeneic cell therapy product, SB623, on patients suffering ... For details regarding this clinical trial, please refer ...
Cached Biology Technology:Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 2Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 3Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 4Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 5Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 6Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 7Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 8Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 9Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders 10Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 2Collins Stewart Announces Formation of Healthcare Investment Banking Alliance 3Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability 2
(Date:4/23/2014)... to their resumes in an effort to aid the ... issues as genomic science transitions to bedside healthcare, a ... , Until now the plays of Karen H. Rothenberg ... by, their peers and others in the genomics community ... Oxford University Press, publication of the book The ...
(Date:4/23/2014)... Indiana University School of Public Health-Bloomington has bolstered the ... finding a strong association between heme iron, found only ... The study found that heme iron consumption increased the ... no association was found between nonheme iron, which is ... disease. , The study was published online ahead of ...
(Date:4/23/2014)... that male black widow spiders prefer their female mates ... mate preference by male spiders. , The ... Andrade, a professor in UTSC,s Department of Biological Sciences, ... that males overwhelmingly chose to mate with well-fed, unmated ... whether a potential mate is well-fed and unmated by ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2
... benefit from treatment with mixtures of customized antibodies. In ... National Academy of Sciences (USA), a team of Weizmann ... form a web that destroys the cancer cell's communication ... intensive cancer research led to the identification of a ...
... seem to occur on Earth roughly every 26 million ... be caused by rare collisions with comets or asteroids. ... that extraordinary predators are at fault instead. , Adam ... many species competing for both food and living space. ...
... to accurately measure the levels of important chemicals in ... level of a single cell. Scientists at the Carnegie ... the first to overcome this obstacle by successfully applying ... brain chemical levels. The sensors alter their 3-dimensional form ...
Cached Biology News:Two are better than one 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3